These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19491622)

  • 1. ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy.
    Kintscher U
    J Hypertens Suppl; 2009 Jun; 27(2):S36-9. PubMed ID: 19491622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
    Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
    J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA; Flaa A; Strand A; Kjeldsen SE
    J Hypertens; 2007 Jan; 25(1):15-23. PubMed ID: 17143167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
    Bang CN; Okin PM; Køber L; Wachtell K; Gottlieb AB; Devereux RB
    J Hypertens; 2014 Mar; 32(3):667-72. PubMed ID: 24379001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
    Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):243-51. PubMed ID: 23403268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan: just an antihypertensive agent? A literature review.
    Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
    Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.
    Wachtell K; Devereux RB; Lyle PA; Okin PM; Gerdts E
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):507-13. PubMed ID: 19124445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for the prevention of stroke.
    Dahlöf B
    J Hypertens Suppl; 2006 Apr; 24(2):S3-9. PubMed ID: 16601558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
    Yamagishi S; Takenaka K; Inoue H
    Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P
    Praxis (Bern 1994); 1996 Feb; 85(8):227-33. PubMed ID: 8701189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials, the renin angiotensin system and atrial fibrillation.
    Birnie DH; Gollob M; Healey JS
    Curr Opin Cardiol; 2006 Jul; 21(4):368-75. PubMed ID: 16755207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of left ventricular remodeling on atrial fibrillation recurrence and cardiovascular hospitalizations in patients undergoing rhythm-control therapy.
    Shah N; Badheka AO; Grover PM; Patel NJ; Chothani A; Mehta K; Hoosien M; Singh V; Savani GT; Deshmukh A; Rathod A; Patel N; Panaich SS; Arora S; Schwartz C; Blisker M; Coffey JO; Mitrani RD; Fuster V; Viles-Gonzalez JF
    Int J Cardiol; 2014 Jun; 174(2):288-92. PubMed ID: 24794553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The question of heart failure in ONTARGET and TRANSCEND: implications for clinical practice.
    González-Juanatey JR
    J Hypertens Suppl; 2009 Jun; 27(2):S32-5. PubMed ID: 19491621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.